Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study

• Published in: Renal failure 2023, Vol.45 (2), p.2256418-2256418
• Main Authors: Sun, Li, Tao, Jun, Han, Zhijian, Chen, Hao, Huang, Zhengkai, Wang, Zijie, Fei, Shuang, Suo, Chuanjian, Ju, Xiaobing, Tan, Ruoyun, Gu, Min
• Format: Article
• Language: English
• Subjects: 25-Hydroxyvitamin D; Alkaline phosphatase; Aorta; Biomarkers; Bone Density; Bone diseases; Bone growth; Bone mineral density; Bone Remodeling; Bone resorption; Bone turnover; Calcification; Calcification (ectopic); Calcium; Calcium (blood); chronic kidney disease; Collagen Type I; Coronary artery; Humans; iguratimod; Kidney transplantation; Kidney Transplantation - adverse effects; Metabolism; mineral and bone disorders; Minerals; Osteocalcin; Osteogenesis; Parathyroid Hormone; Peptides; Phosphorus; Rheumatoid arthritis; Spine (lumbar); Thorax; Transplants & implants; vascular calcification
• ISSN: 0886-022X; 1525-6049
• DOI: 10.1080/0886022X.2023.2256418

Iguratimod has been shown to promote bone formation and inhibit bone resorption in rheumatoid arthritis patients. We aimed to explore its effect on bone metabolism and vascular calcification (VC) in kidney transplant recipients (KTRs). A analysis was conducted among the subjects in our previous randomized clinical trial (NCT02839941). Forty-three KTRs completing bone metabolism 52 weeks after enrollment were selected for this analysis, among whom 27 patients received VC examinations. In the iguratimod group, iguratimod (25 mg twice daily) was added adjuvant to the traditional triple regimen. At the 52-week follow-up, the following parameters were assessed: serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), bone alkaline phosphatase (BALP), osteocalcin, type I collagen N-terminal peptide (NTx), type I collagen C-terminal peptide (CTx), bone mineral density (BMD) of the femoral neck and lumbar spine, coronary artery calcification (CAC) and thoracic aortic calcification (TAC). Bone metabolic and VC indices were compared between the two groups using the independent samples t test and Wilcoxon nonparametric test. At 52 weeks after enrollment, the iguratimod group had lower osteocalcin (  = 0.010), BALP (  = 0.015), NTx (  = 0.007), CTx (  = 0.012), CAC (  = 0.080) and TAC scores (  = 0.036) than the control group. There was no significant difference in serum calcium, phosphorus, 25-hydroxyvitamin D, iPTH and BMD between the groups. Iguratimod could reduce bone turnover markers (BTMs) at both high and low iPTH levels. The adverse effect of iguratimod was mild and tolerable. Iguratimod is safe, can reduce BTMs and may could attenuate VC in the first year after KT.